Prevalence of EILO Among Children With Asthma
Launched by MEDISCH SPECTRUM TWENTE · Jun 26, 2024
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how common Exercise Induced Laryngeal Obstruction (EILO) is among children who have asthma. EILO can make it hard for kids to breathe during exercise, and researchers believe it may occur more often in children with asthma than in the general population. The study aims to find out if about 15% of young asthma patients experience EILO, compared to just 5-8% in teens without asthma.
To participate, children aged 12 to 18 who have been diagnosed with asthma by a doctor may be eligible. They should have shown specific asthma symptoms within the last two years, such as a significant drop in lung function after exercise. Participants will take part in an exercise test, during which doctors will monitor their breathing and ask them questions about their asthma control and breathing difficulties. It’s important to note that those with other serious lung diseases or recent asthma flare-ups won’t be eligible for this study. This research could help improve understanding and treatment for young asthma patients who struggle with breathing during physical activity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 12 to 18 years
- • Paediatrician diagnosed asthma confirmed with at least one of the following during the last two years: Positive ECT (post-exercise fall in FEV1 \> 10%) / Positive methacholine test (PC20 value of ≤8 mg/mL) / Bronchodilator reversibility (increase in FEV1 ≥12% and/or ≥200 mL following inhalation of 200-400 μg short-acting β2-agonists)
- Exclusion Criteria:
- • Other severe cardiopulmonary disease
- • Inability to perform ECT or CLE test
- • Inability to perform technically acceptable spirometry
- • Asthma exacerbation or respiratory tract infection in the last 2 weeks
- • Short-acting β2-agonists or long-acting β2-agonists use less than respectively 8 and 24 hours before the ECT or CLE test
- • Oral corticosteroid use in the 4 weeks before the ECT or CLE test
About Medisch Spectrum Twente
Medisch Spectrum Twente (MST) is a leading healthcare institution located in the Netherlands, dedicated to providing high-quality medical care and advancing clinical research. As a regional hospital, MST is committed to improving patient outcomes through innovative treatment options and comprehensive clinical trials. The institution fosters collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic partners, ensuring a robust environment for conducting research that adheres to the highest ethical standards. MST's focus on patient-centered care and its strategic initiatives in clinical research contribute significantly to the advancement of medical knowledge and the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Enschede, Overijssel, Netherlands
Patients applied
Trial Officials
Vera Hengeveld, MD
Principal Investigator
Medisch Spectrum Twente
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported